Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05100862
Title A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Marginal Zone Lymphoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors BeiGene

marginal zone B-cell lymphoma


Rituximab + Zanubrutinib

Lenalidomide + Rituximab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.